Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05651> ?p ?o ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05651 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05651 label "MGCD-0103 [drugbank:DB05651]" assertion.
- drugbank:DB05651 seeAlso DB05651 assertion.
- drugbank:DB05651 identifier "drugbank:DB05651" assertion.
- drugbank:DB05651 description "MethylGene Inc, in collaboration with Pharmion Corp, is developing the small-molecule, isoform-selective compound MGCD-0103 in North America for the potential treatment of cancer. MGCD-0103 is currently undergoing phase II clinical trials in patients with lymphoma, leukemia, myelodysplastic syndromes and solid tumors, including pancreatic carcinoma. Taiho Pharmaceutical Co Ltd is evaluating MGCD-0103 for oncological indications in South East Asia." assertion.
- drugbank:DB05651 title "MGCD-0103" assertion.
- drugbank:DB05651 bio2rdf_vocabulary:identifier "DB05651" assertion.
- drugbank:DB05651 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05651 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05651" assertion.
- drugbank:DB05651 bio2rdf_vocabulary:x-identifiers.org DB05651 assertion.
- drugbank:DB05651 drugbank_vocabulary:drugbank-id "DB05651" assertion.
- drugbank:DB05651 drugbank_vocabulary:x-cas cas: assertion.